Whitepaper
Translational Data and the Next Era of Drug Development.
Drug development does not lack data. It lacks consistently decision-grade translational evidence.
Written by Jessica Miller, Founder and Managing Partner of RocketBio, with Dr. Julie Frearson, Global Executive Lead, Discovery Sciences at IQVIA Laboratories, and contributions from Dr. Pierre Morgon (RocketBio) and Dr. Marina Kolocha (Syneos Health).

Drug development does not lack data. It lacks consistently decision-grade translational evidence.
At the RocketBio Reception in San Diego, held alongside BIO International 2026, we brought together leaders from biopharma, CROs and life sciences technology to discuss how translational data will shape the next era of drug development. This whitepaper captures the insights from that evening.
Written by Jessica Miller, Founder and Managing Partner of RocketBio, with Dr. Julie Frearson, Global Executive Lead, Discovery Sciences at IQVIA Laboratories, and contributions from Dr. Pierre Morgon (RocketBio) and Dr. Marina Kolocha (Syneos Health).
Key themes include why poor translation is most costly at Phase II, why human relevance and predictive performance drive go or no-go decisions, why context of use matters more than universal validation, and why AI is an enabler rather than a substitute for well-anchored data.
